This will be a phase II, single arm study of osteosarcoma patients with fully resected
pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer
of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland
for the treatment of solid tumors and precancerous lesions.
The study population includes patients with relapse of osteosarcoma in the lung following
surgical resection of all gross disease (2nd or greater CR). Following completion of final
thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with
surveillance imaging via CT scan to monitor for relapsed disease.
Phase:
Phase 2
Details
Lead Sponsor:
Hackensack Meridian Health
Collaborators:
Iscador AG, Arlesheim, Switzerland. M.D. Anderson Cancer Center Susan Zabransky Hughes Foundation Tackle Kids Cancer